Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer (proSPECT-AS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02615067 |
Recruitment Status :
Completed
First Posted : November 25, 2015
Last Update Posted : April 10, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Prostate Cancer | Drug: 99mTc-MIP-1404 Injection Diagnostic Test: Whole-Body Planar and pelvic SPECT/CT scan | Phase 3 |
This is a multi-center, multi-reader, open-label trial, comparing 99mTc-MIP-1404 SPECT/CT imaging in men who have had a diagnostic trans-rectal ultrasound (TRUS) guided biopsy with a histopathologic finding of Gleason score ≤3+4 who are candidates for active surveillance and are undergoing routine biopsy or voluntary RP with or without a pelvic lymph node dissection (PLND). This study will evaluate the sensitivity and specificity of 99mTc-MIP-1404 SPECT/CT image assessments to correctly identify subjects with previously unknown clinically significant prostate cancer in two cohorts: (1) Low grade prostate cancer who have elected to undergo RP [Cohort A]; and (2) very low risk (VLR) prostate cancer per 2016 NCCN Guidelines who are scheduled to undergo routine prostate biopsy [Cohort B].
Subjects will receive a single dose of 99mTc-MIP-1404 Injection (study drug) followed by whole body planar and SPECT/CT (pelvic) imaging 3-6 hours after injection. In accordance with standard of care procedures, subjects will undergo either voluntary RP [Cohort A] or prostate biopsy [Cohort B] within 42 days after study drug dosing. 99mTc-MIP-1404 image data will be collected by a central imaging core laboratory and evaluated for visible uptake within the prostate gland. These findings will then be compared against central histopathology as the truth standard. The central imaging core lab independent readers for the SPECT/CT scans will be blinded to all clinical data, including pathology results. Likewise, central pathologists are to remain blinded to all clinical data, including imaging results.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 531 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS) |
Study Start Date : | December 2015 |
Actual Primary Completion Date : | December 28, 2017 |
Actual Study Completion Date : | December 28, 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: 99mTc-MIP-1404 Injection
20 ± 3 millicurie (mCi) intravenous (IV) injection of 99mTc-MIP-1404
|
Drug: 99mTc-MIP-1404 Injection
A single dose of 20 (±3) mCi intravenous (IV) injection of 99mTc-MIP-1404.
Other Name: 1404 Diagnostic Test: Whole-Body Planar and pelvic SPECT/CT scan A whole-body planar and pelvic SPECT/CT scan will be obtained 3-6 hours after injection of 99mTc-MIP-1404. |
- Specificity of 99mTc-MIP-1404 to detect clinically significant prostate cancer when compared to histopathology following either RP [Cohort A] or prostate biopsy [Cohort B] [ Time Frame: Within 3-6 hours of dosing, SPECT/CT and whole body planar images will be taken ]Tissue distribution of 99mTc-MIP-1404 SPECT/CT imaging in tumor and non-tumorous regions of the prostate and pelvic lymph nodes, if applicable, (as determined by histopathology) in patients undergoing RP (with or without extended pelvic lymph node dissection) or routine prostate biopsy. Pathology results will be used as the truth standard for all imaging analyses.
- Sensitivity of 99mTc-MIP-1404 to detect clinically significant prostate cancer when compared to histopathology following either RP [Cohort A] or prostate biopsy [Cohort B] [ Time Frame: Within 3-6 hours of dosing, SPECT/CT and whole body planar images will be taken ]Tissue distribution of 99mTc-MIP-1404 SPECT/CT imaging in tumor and non-tumorous regions of the prostate and pelvic lymph nodes (as determined by histopathology) in patients undergoing standard of care prostatectomy with or without extended pelvic lymph node dissection. Pathology results will be used as the truth standard for all imaging analyses.
- Sensitivity of 99mTc-MIP-1404 in prostate segments as compared to histopathology following RP [Cohort A only] [ Time Frame: Within 3-6 hours of dosing, SPECT/CT and whole body planar images will be taken ]Tissue distribution of 99mTc-MIP-1404 SPECT/CT imaging in tumor and non-tumorous regions of the prostate (as determined by histopathology)
- Specificity of 99mTc-MIP-1404 in prostate segments as compared to histopathology following RP [Cohort A only] [ Time Frame: Within 3-6 hours of dosing, SPECT/CT and whole body planar images will be taken ]Tissue distribution of 99mTc-MIP-1404 SPECT/CT imaging in tumor and non-tumorous regions of the prostate (as determined by histopathology)
- Clinical safety of 99mTc-MIP-1404 [ Time Frame: Changes in vital signs and clinical laboratory test results from time of screening until pre-surgery (Day 0 - 42). Treatment-emergent adverse events from study drug injection until pre-surgery or pre-biopsy (within 42 days) ]Clinical laboratory tests will include hematology and clinical chemistry. Vital signs will include heart rate, blood pressure, temperature and respiration rate.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
INCLUSION CRITERIA:
- Ability to provide informed consent and willingness to comply with protocol requirements
- Life expectancy ≥ 6 months
Cohort A only:
- A diagnostic trans-rectal ultrasound (TRUS)-guided biopsy within 12 months of enrollment showing adenocarcinoma of the prostate gland
- Within 90 days of consent, serum PSA ≤ 15.0 ng/mL or ≤ 7.5 ng/mL if on 5 α-reductase inhibitors.
- Candidates for active surveillance and/or a Gleason score ≤3+4
- Scheduled to undergo radical prostatectomy (RP) with or without pelvic lymph node dissection (PLND)
Cohort B only:
- Very low risk (VLR) prostate cancer defined by 2016 NCCN Guideline criteria:
- T1c stage, and
- PSA < 10 ng/mL, and
- Gleason score ≤ 6 with < 3 biopsy cores cancer positive and ≤ 50% cancer in any core based on prior prostate biopsy within 24 months of enrollment, and
- PSA density < 0.15 mg/mL/g
- Scheduled to undergo a reassessment of prostate cancer staging that includes prostate biopsy as part of routine follow-up
EXCLUSION CRITERIA:
- Subjects administered a radioisotope within 5 physical half-lives prior to study drug injection.
- Previous treatment with hormonal therapy, surgery (except biopsy), radiation therapy, LHRH analogs, and non-steroidal anti-androgens, for the treatment of prostate cancer or benign prostatic hyperplasia (BPH)
- Planned androgen or anti-androgen therapy prior to RP surgery or biopsy
- Subjects with any medical condition or other circumstances that, in the opinion of the investigator, would significantly interfere with obtaining reliable data, achieving study objectives, or completing the study
- Malignancy (not including curatively treated basal or squamous cell carcinoma of the skin) within the previous 5 years. (Ta stage transitional cell carcinoma bladder cancer with negative surveillance cystoscopy within the past 2 years may be included).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02615067

Study Chair: | William Ellis, MD | University of Washington |
Responsible Party: | Molecular Insight Pharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT02615067 |
Other Study ID Numbers: |
MIP-1404-3301 |
First Posted: | November 25, 2015 Key Record Dates |
Last Update Posted: | April 10, 2019 |
Last Verified: | April 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Diagnostic Active surveillance Very low risk Imaging PSMA |
SPECT/CT 99mTc Newly Diagnosed Prostatectomy Biopsy |
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms |
Neoplasms by Site Neoplasms Prostatic Diseases |